Novo Nordisk sued rival in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo‘s drugs.

Subscribe to read this story ad-free

Get unlimited access to ad-free articles and exclusive content.

The Danish company filed the lawsuit in U.S. District Court in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo‘s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.

“The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines,” Novo wrote in its complaint.

But Indianapolis-based Eli Lilly said it stands firmly behind its ads, which are based on the results of its SURMOUNT-5 trial. That trial — completed in 2024 — compared patients on 10 mg or 15 mg of Lilly’s Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy. The FDA approved a 7.2 mg dose of Wegovy in March of this year.

“Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial,” a Lilly spokesperson said in a...

Read Full Story: https://news.google.com/rss/articles/CBMiugFBVV95cUxObHVlS205Qk9NdXlJcUxrb3Jw...